260 related articles for article (PubMed ID: 11348665)
1. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody.
Chen W; Yu Y; Shao C; Zhang M; Wang W; Zhang L; Cao X
Immunol Lett; 2001 May; 77(1):17-23. PubMed ID: 11348665
[TBL] [Abstract][Full Text] [Related]
2. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines.
Rieger R; Kipps TJ
Cancer Res; 2003 Jul; 63(14):4128-35. PubMed ID: 12874017
[TBL] [Abstract][Full Text] [Related]
3. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
Decker T; Schneller F; Sparwasser T; Tretter T; Lipford GB; Wagner H; Peschel C
Blood; 2000 Feb; 95(3):999-1006. PubMed ID: 10648415
[TBL] [Abstract][Full Text] [Related]
4. Enhanced T cell-independent antibody responses in c-Jun N-terminal kinase 2 (JNK2)-deficient B cells following stimulation with CpG-1826 and anti-IgM.
Cao Y; Takada E; Hata K; Sudo K; Furuhata M; Mizuguchi J
Immunol Lett; 2010 Aug; 132(1-2):38-44. PubMed ID: 20665951
[TBL] [Abstract][Full Text] [Related]
5. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens.
Jahrsdörfer B; Hartmann G; Racila E; Jackson W; Mühlenhoff L; Meinhardt G; Endres S; Link BK; Krieg AM; Weiner GJ
J Leukoc Biol; 2001 Jan; 69(1):81-8. PubMed ID: 11200072
[TBL] [Abstract][Full Text] [Related]
6. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor.
Liu HM; Newbrough SE; Bhatia SK; Dahle CE; Krieg AM; Weiner GJ
Blood; 1998 Nov; 92(10):3730-6. PubMed ID: 9808567
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens.
Kovarik J; Bozzotti P; Tougne C; Davis HL; Lambert PH; Krieg AM; Siegrist CA
Immunology; 2001 Jan; 102(1):67-76. PubMed ID: 11168639
[TBL] [Abstract][Full Text] [Related]
8. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells.
Sparwasser T; Koch ES; Vabulas RM; Heeg K; Lipford GB; Ellwart JW; Wagner H
Eur J Immunol; 1998 Jun; 28(6):2045-54. PubMed ID: 9645386
[TBL] [Abstract][Full Text] [Related]
9. CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells.
Ponzio NM; Cutro S; Hu J; Marzouk A; Marshall JD
Int Immunopharmacol; 2006 Dec; 6(13-14):2057-68. PubMed ID: 17161362
[TBL] [Abstract][Full Text] [Related]
10. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells.
Warren TL; Bhatia SK; Acosta AM; Dahle CE; Ratliff TL; Krieg AM; Weiner GJ
J Immunol; 2000 Dec; 165(11):6244-51. PubMed ID: 11086059
[TBL] [Abstract][Full Text] [Related]
11. Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides.
Brummel R; Lenert P
J Immunol; 2005 Feb; 174(4):2429-34. PubMed ID: 15699180
[TBL] [Abstract][Full Text] [Related]
12. [Regulatory B cells activated by CpG-ODN combined with anti-CD40 monoclonal antibody inhibit CD4(+)T cell proliferation].
Wang K; Tao L; Su J; Zhang Y; Zou B; Wang Y; Li X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Sep; 32(9):1164-7. PubMed ID: 27609568
[TBL] [Abstract][Full Text] [Related]
13. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
Carpenter EL; Mick R; Rüter J; Vonderheide RH
J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
[TBL] [Abstract][Full Text] [Related]
14. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.
Hartmann G; Weeratna RD; Ballas ZK; Payette P; Blackwell S; Suparto I; Rasmussen WL; Waldschmidt M; Sajuthi D; Purcell RH; Davis HL; Krieg AM
J Immunol; 2000 Feb; 164(3):1617-24. PubMed ID: 10640783
[TBL] [Abstract][Full Text] [Related]
15. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA.
Wagner M; Poeck H; Jahrsdoerfer B; Rothenfusser S; Prell D; Bohle B; Tuma E; Giese T; Ellwart JW; Endres S; Hartmann G
J Immunol; 2004 Jan; 172(2):954-63. PubMed ID: 14707068
[TBL] [Abstract][Full Text] [Related]
16. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody.
Tutt AL; O'Brien L; Hussain A; Crowther GR; French RR; Glennie MJ
J Immunol; 2002 Mar; 168(6):2720-8. PubMed ID: 11884438
[TBL] [Abstract][Full Text] [Related]
17. T-cell activation induced by anti-CD3 x anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand.
Wooldridge JE; Dahle CE; Weiner GJ
Cancer Immunol Immunother; 1997; 45(3-4):174-9. PubMed ID: 9435867
[TBL] [Abstract][Full Text] [Related]
18. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.
Wooldridge JE; Ballas Z; Krieg AM; Weiner GJ
Blood; 1997 Apr; 89(8):2994-8. PubMed ID: 9108420
[TBL] [Abstract][Full Text] [Related]
19. CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms.
Askew D; Chu RS; Krieg AM; Harding CV
J Immunol; 2000 Dec; 165(12):6889-95. PubMed ID: 11120813
[TBL] [Abstract][Full Text] [Related]
20. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
